Form 4: ACAD CEO Adams Reports RSU Vesting, Tax-Related Stock Sale

ACADIA Pharmaceuticals CEO Catherine Owen Adams reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• CEO Catherine Owen Adams acquired 23,509 shares of ACADIA Pharmaceuticals common stock on March 24, 2026, through the vesting of Restricted Stock Units (RSUs).
• On March 25, 2026, Adams sold 11,641 shares of common stock at a price of $21.47 per share.
• The sale was a mandatory transaction to cover withholding taxes and tax-related items associated with the RSU vesting.
• The transaction was executed under a Rule 10b5-1 plan, intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B).
• Following these transactions, Adams directly owns 14,803 shares of common stock and 70,530 Restricted Stock Units.
• The reported beneficial ownership of common stock includes 2,935 shares acquired on May 15, 2025, via an employee stock purchase plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there's a stock sale, it's for tax purposes following RSU vesting, which is a positive compensation event for the CEO and aligns her interests with shareholders.

Positives

• Vesting of 23,509 Restricted Stock Units indicates continued compensation and retention of the CEO.
• The CEO continues to hold a significant number of shares (14,803) and unvested RSUs (70,530), aligning her interests with shareholders.

Negatives

• Sale of 11,641 shares reduces the CEO's direct common stock holdings, although this was for tax purposes.

Future Outlook

The remaining 70,530 Restricted Stock Units held by the CEO are scheduled to vest in three additional equal annual installments following the initial vesting on March 24, 2026.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as those related to RSU vesting and subsequent tax-related sales, are common in the biotechnology and pharmaceutical sectors. These transactions typically reflect standard executive compensation practices rather than a change in management's outlook on the company's prospects. The sale to cover taxes is a standard practice and not indicative of a lack of confidence.

Comparison to Industry Standards

• These types of transactions are standard for executive compensation in publicly traded companies, particularly in the biotech sector.
• For example, similar tax-related sales following RSU vesting are frequently observed among executives at companies like Biogen Inc. (BIIB) or Gilead Sciences, Inc. (GILD), where equity compensation forms a significant part of total remuneration.
• The reported sale price of $21.47 per share is specific to ACAD's stock performance at the time of the transaction and is not directly comparable to other companies' stock prices without further context on their respective valuations and market conditions.

Stakeholder Impact

• Shareholders: The CEO's continued equity holdings (common stock and RSUs) align her interests with shareholders, though the tax-related sale slightly reduces her direct common stock ownership.
• Employees: The RSU vesting and ESPP acquisition demonstrate standard employee equity compensation practices within the company.

Next Steps

• Remaining 70,530 Restricted Stock Units will vest in three additional equal annual installments, starting from March 24, 2026.

Key Dates

Recommendation

This Form 4 reports routine insider transactions related to executive compensation (RSU vesting and subsequent tax-related sales). Such events are generally neutral and do not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. The CEO's continued significant equity holdings suggest ongoing alignment with shareholder interests.

Keywords

ACADIA Pharmaceuticals, ACAD, Catherine Owen Adams, CEO, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Stock Sale, Rule 10b5-1, Employee Stock Purchase Plan